10:09 AM EST - ProMIS Neurosciences Inc : Announced an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA. The presentations highlight ProMIS’ broad pipeline of next-generation neurodegenerative disease therapeutics, including data that further characterize lead drug AD candidate, PMN310, as well as preclinical optimization studies of an Alzheimer’s vaccine and data supporting RACK1 as a potential target in amyotrophic lateral sclerosis (ALS). ProMIS Neurosciences Inc
shares T.PMN are trading -$0.15 at $6.30.
